MX2015009392A - Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias. - Google Patents

Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.

Info

Publication number
MX2015009392A
MX2015009392A MX2015009392A MX2015009392A MX2015009392A MX 2015009392 A MX2015009392 A MX 2015009392A MX 2015009392 A MX2015009392 A MX 2015009392A MX 2015009392 A MX2015009392 A MX 2015009392A MX 2015009392 A MX2015009392 A MX 2015009392A
Authority
MX
Mexico
Prior art keywords
tnf
inflammatory disease
combination therapy
therapy biomarkers
biomarkers
Prior art date
Application number
MX2015009392A
Other languages
English (en)
Inventor
Jeffrey W Voss
Carolyn A Cuff
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015009392A publication Critical patent/MX2015009392A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención proporciona métodos para predecir la eficacia de terapias de combinación anti-TNF y antiÏTL17, en el tratamietno de un sujeto que padece una enfermedad inflamatoria, mediante la determinación de la concentración de los marcadores CXCL1 y/o CXCL5, en una muestra proveniente del sujeto.
MX2015009392A 2013-01-21 2014-01-21 Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias. MX2015009392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754917P 2013-01-21 2013-01-21
PCT/US2014/012364 WO2014113804A1 (en) 2013-01-21 2014-01-21 Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease

Publications (1)

Publication Number Publication Date
MX2015009392A true MX2015009392A (es) 2015-10-15

Family

ID=50073489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009392A MX2015009392A (es) 2013-01-21 2014-01-21 Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.

Country Status (10)

Country Link
US (1) US20140205613A1 (es)
EP (1) EP2946214A1 (es)
JP (1) JP2016506720A (es)
CN (1) CN105190314A (es)
AU (1) AU2014207321A1 (es)
BR (1) BR112015017403A2 (es)
CA (1) CA2897997A1 (es)
MX (1) MX2015009392A (es)
TW (1) TW201514310A (es)
WO (1) WO2014113804A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291689A1 (en) * 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MX2017008660A (es) * 2015-01-12 2017-11-17 Affibody Ab Polipeptidos enlazados a il-17a.
US20160244520A1 (en) * 2015-01-24 2016-08-25 Abbvie Inc. Compositions and methods for treating psoriatic arthritis
DK3359688T3 (da) * 2015-10-05 2021-08-23 Biogen Ma Inc Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
CN106119348B (zh) * 2016-06-27 2018-02-23 中南大学湘雅医院 一种以非编码lnc‑CXCL1及编码基因cxcl1组合为检测或诊断筛查标志物的重症肌无力检测试剂盒及应用
CN107860830A (zh) * 2017-10-10 2018-03-30 暨南大学 一种寻常型银屑病血浆中生物标志物在其靶向药物的应用
CN107661501B (zh) * 2017-11-03 2020-04-28 中山大学孙逸仙纪念医院 一种治疗强直性脊柱炎的药物组合物、药物靶点及其应用
CN109796534B (zh) * 2017-11-16 2021-08-10 北京比洋生物技术有限公司 抗il-17抗体/tnfr ecd融合蛋白及其用途
WO2020139620A1 (en) * 2018-12-26 2020-07-02 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
WO2021256524A1 (ja) * 2020-06-18 2021-12-23 国立大学法人京都大学 免疫原性低減型低分子抗体とその製造法
CN116769027B (zh) * 2023-06-09 2023-12-01 康元医疗科技(大连)有限公司 一种抗il-17纳米抗体、多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix Inc N D Ges D Staat Verfahren zur Herstellung von Polymerarrays
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6033860A (en) 1997-10-31 2000-03-07 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
EP2403531A4 (en) 2009-03-05 2013-02-27 Abbott Lab IL-17 BINDING PROTEINS
CA2839792A1 (en) * 2011-05-10 2012-11-15 Nestec S.A. Methods of disease activity profiling for personalized therapy management

Also Published As

Publication number Publication date
EP2946214A1 (en) 2015-11-25
TW201514310A (zh) 2015-04-16
CA2897997A1 (en) 2014-07-24
WO2014113804A9 (en) 2015-07-09
BR112015017403A2 (pt) 2017-11-21
US20140205613A1 (en) 2014-07-24
AU2014207321A1 (en) 2015-07-23
JP2016506720A (ja) 2016-03-07
CN105190314A (zh) 2015-12-23
WO2014113804A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
MX2015009392A (es) Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
PH12016500302A1 (en) Compositions and method for treating complement-associated conditions
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
MX2017004742A (es) Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
CL2015000192A1 (es) Método de seleccion de un sujeto que padece un tumor maligno para tratamiento con inhibidor de jak/stat que comprende determinar nivel de expresión de biomarcadores.
MX357429B (es) Predictores para el tratamiento del cáncer.
WO2013185779A3 (en) Biomarkers for prostate cancer
MA40636A (fr) Procédés pour détecter le cancer de la prostate
MX2016017097A (es) Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2).
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
MX2018009112A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico.
MX2018006250A (es) Biomarcador de enfermedad poliquistica renal y usos del mismo.
UA96549U (uk) Спосіб прогнозування зрощення перелому
UA96515U (uk) Спосіб прогнозування зрощення перелому
LV14902A (lv) Olnīcu vēža riska noteikšanas paņēmiens sievietēm ar veidojumu dzemdes piedēkļu rajonā
UA96596U (uk) Спосіб прогнозування зрощення перелому
UA96623U (uk) Спосіб прогнозування зрощення перелому
UA96926U (uk) Спосіб прогнозування зрощення перелому
UA96652U (uk) Спосіб прогнозування зрощення перелому